Clinical Activity
NSCLC, PD, tumor, death
TUMOR, DISEASE, BEST, SMALL CELL LUNG CANCER, NSCLC
Seventeen patients (80.9%) had follow-up scans after baseline to evaluate tumor response. Their best tumor response is shown in Best objective response. NSCLC: non–small cell lung cancer; PD: progressive disease; SD: stable disease. Note: Waterfall plot of patients treated with Helixor-M and had follow-up scans after baseline to evaluate tumor response (
Time to stable disease, progressive disease, and death. NSCLC: non–small cell lung cancer; PD: progressive disease; SD: stable disease. Note: Time to stable disease, progression, and death of all patients treated with Helixor-M (